741. Elicitation of expert prior opinion to design the BARJDM trial in juvenile dermatomyositis.
作者: Charalampia Papadopoulou.;Neil Martin.;Nadia Rafiq.;Liza McCann.;Giulia Varner.;Kerstin Nott.;Sandrine Compeyrot-Lacassagne.;Maria Leandro.;Charlene Foley.;Kishore Warrier.;Nathan Green.;Mandy Wan.;Hakim-Moulay Dehbi.;John Whitehead.;Despina Eleftheriou.;Paul Brogan.
来源: Rheumatology (Oxford). 2024年63卷12期3271-3278页
To elicit and quantify expert opinion concerning the relative merits of two treatments for a rare inflammatory disease: JDM. The formal expression of expert opinion reported in this article will be used in a Bayesian analysis of a forthcoming randomized controlled trial known as BARJDM (baricitinib for JDM).
742. Effectiveness of pneumococcal vaccination in adults with common immune-mediated inflammatory diseases in the UK: a case-control study.
作者: Georgina Nakafero.;Matthew J Grainge.;Tim Card.;Christian D Mallen.;Jonathan S Nguyen Van-Tam.;Abhishek Abhishek.
来源: Lancet Rheumatol. 2024年6卷9期e615-e624页
People with immune-mediated inflammatory disease are at increased risk of pneumococcal pneumonia. The effectiveness of pneumococcal vaccination in people with immune-mediated inflammatory diseases has not been evaluated. We investigated the effectiveness of pneumococcal vaccination in preventing morbidity and mortality associated with pneumonia in patients with immune-mediated inflammatory diseases.
743. Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project.
作者: Francesco Baldo.;Remco G A Erkens.;Mao Mizuta.;Greta Rogani.;Federica Lucioni.;Claudia Bracaglia.;Dirk Foell.;Marco Gattorno.;Marija Jelusic.;Jordi Anton.;Paul Brogan.;Scott Canna.;Shanmuganathan Chandrakasan.;Randy Q Cron.;Fabrizio De Benedetti.;Alexei Grom.;Merav Heshin-Bekenstein.;AnnaCarin Horne.;Raju Khubchandani.;Seza Ozen.;Pierre Quartier.;Angelo Ravelli.;Masaki Shimizu.;Grant Schulert.;Christiaan Scott.;Rashmi Sinha.;Nicolino Ruperto.;Joost F Swart.;Sebastiaan Vastert.;Francesca Minoia.; .
来源: Rheumatology (Oxford). 2025年64卷1期32-44页
To assess current treatment in macrophage activation syndrome (MAS) worldwide and to highlight any areas of major heterogeneity of practice.
744. Assessment of neurocognitive function in patients with Behçet's disease.
There is limited knowledge on cognitive performance in Behçet's disease (BD), the majority of which come from patients with neuro-Behçet's disease. However, the influence of BD on cognitive function in patients without neurological involvement is still not well understood.The aim of the study was to determine the frequency of cognitive involvement in BD patients without evident neuropsychiatric symptoms and to identify associated clinical variables in those patients.
745. Preliminary test of Polish translation of the Rheumatoid and Arthritis Outcome Score - observational study.
作者: Łukasz Pulik.;Adam Zalewski.;Nicola Dyrek.;Wiktoria Skała.;Paweł Łęgosz.
来源: Reumatologia. 2024年62卷3期157-160页
Today, patients with inflammatory joint diseases participate in more physical activities, including sports and recreation. The tools currently used to assess quality of life and functioning in rheumatic diseases, available in Polish, do not address these problems. The Rheumatoid and Arthritis Outcome Score (RAOS) questionnaire was developed but is not available in the Polish language. This tool is used to evaluate the functional limitations of physically active people who suffer from arthritis and associated lower limb disorders. The objective of this study is the translation and cross-cultural adaptation of the RAOS into Polish.
746. Disease activity and fatigue in inflammatory arthritis patients with different dietary preferences: a retrospective exploratory cross-sectional study.
作者: Dmytro Fedkov.;Christine Peine.;Abdullah Khalil.;Felix Lang.
来源: Reumatologia. 2024年62卷3期161-168页
Recently, diet has received considerable attention as an important factor in inflammatory arthritis. The objective of this study was to evaluate disease activity and fatigue in patients with rheumatoid arthritis and spondyloarthritis (including psoriatic arthritis) depending on their dietary preferences.
747. Usefulness in daily practice of the Systemic Lupus Erythematosus Disease Activity Index 2000 scale and the Systemic Lupus Erythematosus Disease Activity Score index for assessing the activity of systemic lupus erythematosus.
作者: Dorota Suszek.;Maciej Dubaj.;Karol Bigosiński.;Aleksandra Dembowska.;Marcin Kaniewski.;Wiktoria Sielwanowska.;Bartosz Skierkowski.;Izabela Dzikowska.;Julia Sieczka.;Maria Majdan.
来源: Reumatologia. 2024年62卷3期187-195页
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by high heterogeneity of clinical manifestations and an uncertain prognosis. Although the mortality rate due to SLE has decreased significantly in recent decades, there is still a need to find good tools to measure disease activity for early detection of exacerbations and treatment planning. Over the decades, more than a dozen disease activity scales/indicators have been developed, with the SLE Disease Activity Index (SLEDAI) being the most popular. More recently, the new SLE Disease Activity Score (SLE-DAS) has been introduced. This paper compares the two methods of assessing SLE activity, and presents the relevance of these scales in pregnant SLE patients and their use in formulating definitions of remission and low disease activity. The results show that the SLEDAI and the SLE-DAS are of comparable value in assessing SLE activity and complement each other.
749. The problem of residual pain in the assessment of rheumatoid arthritis activity.
Residual pain is a major unmet medical need observed in patients suffering from rheumatoid arthritis (RA), which decreases their quality of life, even after achieving remission or low disease activity. The article has two aims: 1) to present mechanisms involved in the pathophysiology of residual pain, both inflammatory and non-inflammatory, i.e. neuropathic and nociplastic pain, as well as secondary pain syndromes, i.e. osteoarthritis and fibromyalgia, which can contribute to residual pain; 2) to show the limitations of current disease activity measures recommended by European Alliance of Associations for Rheumatology (EULAR) and American College of Rheumatology (ACR), which raise the need for a separate assessment of pain, and examples of methods that could be used by medical professionals to assess the pain and make a differential diagnosis. In conclusion, establishing a valid method to assess pain is essential to identify the pathomechanism of residual pain and to create treatments tailored specifically to individual RA patients.
750. An epidemiological study of multisystem inflammatory syndrome in children (MIS-C) and young adults among COVID-19-positive patients - data from National Inpatient Sample database.
作者: Shruti Aggarwal.;Jasninder Singh Dhaliwal.;Nomesh Kumar.;Hemamalini Sakthivel.;Raheel Ahmed.;Renuka Verma.;Kamleshun Ramphul.
来源: Reumatologia. 2024年62卷3期214-216页
During the pandemic of COVID-19, a novel atypical set of clinical findings was seen among several children with recent or current exposure to the virus. It was termed the "multisystem inflammatory syndrome in children" (MIS-C). Our study used the 2021 National Inpatient Sample to study the associations of sex, race, and age with the incidence of MIS-C among COVID-19-positive children. Out of 69,440 COVID-19-positive children, 2,790 (4.0%) reported MIS-C. The incidence of MIS-C was highest among those aged 8 years old (17,130 MIS-C cases per 100,000 COVID-19 patients), Asian or Pacific Islanders (API) (5,346 MIS-C per 100,000 COVID-19 cases), and males (4,734 cases per 100,000 COVID-19 cases). Furthermore, 7.9% of MIS-C cases met the classification of Kawasaki disease.
751. Early predictive factors in routine clinical practice for rituximab therapy response in patients with rheumatoid arthritis.
作者: Evgenija Mihajloska.;Aleksandar Dimkovski.;Aleksandra Grozdanova.;Ana Vasilevska.;Dubravka Antova.;Zorica Naumovska.;Aleksandra Kapedanovska Nestorovska.;Zoran Sterjev.;Bashkim Osmani.;Ljubica Shuturkova.
来源: Reumatologia. 2024年62卷3期150-156页
Identifying early predictive factors of how rheumatoid arthritis (RA) patients respond to rituximab (RTX) treatment is crucial for both individual treatment outcome and the improvement of clinical practice overall. This study aimed to identify early predictive factors available in standard clinical practice for predicting RTX treatment outcomes in RA patients.
752. Hyperuricemia - consequences of not initiating therapy. Benefits and drawbacks of treatment.
作者: Igor Domański.;Aleksandra Kozieł.;Natalia Kuderska.;Paulina Wójcik.;Łucja Dudzik.;Tomasz Dudzik.
来源: Reumatologia. 2024年62卷3期207-213页
Hyperuricemia, characterized by elevated levels of uric acid in the body, is associated with several health risks, including gout, urolithiasis and cardiovascular disease. Although treatment options are available, they can lead to hypersensitivity reactions, particularly with allopurinol therapy. This paper provides a comprehensive review of the consequences of hyperuricemia, the need for treatment and the potential adverse effects of allopurinol, illustrated by a case study. The study highlights the importance of careful consideration before initiating therapy, particularly in patients with comorbidities and concomitant medication. It emphasizes the need for vigilant monitoring and individualized treatment approaches to reduce adverse effects. In addition, genetic factors, particularly HLA-B*5801, play an important role in determining susceptibility to allopurinol hypersensitivity reactions. This paper highlights the importance of informed decision making in the management of hyperuricemia to optimize patient outcomes while minimizing the risks associated with treatment.
753. Magnetic resonance imaging of the musculoskeletal system in the diagnosis of rheumatic diseases in the pediatric population.
作者: Joanna Ożga.;Elżbieta Mężyk.;Wojciech Kmiecik.;Wadim Wojciechowski.;Zbigniew Żuber.
来源: Reumatologia. 2024年62卷3期196-206页
Magnetic resonance imaging (MRI) of the musculoskeletal system is an examination increasingly performed for suspected juvenile idiopathic arthritis, chronic nonbacterial osteomyelitis and juvenile idiopathic inflammatory myopathies, as well as other rheumatic diseases of developmental age. T1-, T2- and PD-weighted with or without fat suppression or short tau inversion recovery/turbo inversion recovery magnitude (STIR/TIRM) sequences and post-contrast sequences are evaluated to diagnose pathological changes in the synovial membrane, subchondral bone marrow and surrounding soft tissues. Magnetic resonance imaging allows detection of synovitis, tenosynovitis, bursitis, and enthesitis as well as bone marrow edema and soft tissue edema. Several pediatric-specific MRI scoring systems have been developed and validated to standardize and facilitate the assessment of the extent of the inflammatory process and disease activity in MRI. Early detection of inflammatory changes allows the inclusion of comprehensive pharmacotherapy giving the possibility of permanent remission and objective measurement of the effectiveness of treatment.
754. Distinctive clinical traits of lupus-related myocarditis: a multicentre retrospective study.
作者: Giuseppe A Ramirez.;Noora E A Holopainen.;Maria Gerosa.;Giacomo De Luca.;Chiara Bellocchi.;Daniel Arroyo-Sánchez.;Simone Sala.;Giovanni Peretto.;Luca Moroni.;Francesca Mastropaolo.;Lorenza M Argolini.;Giuseppe Pizzetti.;Anna Palmisano.;Antonio Esposito.;Adriana Cariddi.;Silvia Sartorelli.;Corrado Campochiaro.;Lorenzo Beretta.;Enrica P Bozzolo.;Roberto Caporali.;Lorenzo Dagna.
来源: Rheumatology (Oxford). 2025年64卷4期1904-1911页
Cardiovascular involvement in systemic lupus erythematosus (SLE) is frequent, but little is known about possible distinctive traits of SLE-related myocarditis (myoSLE) in comparison with patients with SLE (onlySLE) or myocarditis alone (onlyMyo).
755. Enhanced surveillance for the detection of psoriatic arthritis in a UK primary care psoriasis population: results from the TUDOR trial.
作者: Neil McHugh.;William Tillett.;Philip Helliwell.;Jonathan Packham.;Howard Collier.;Claire Davies.;Myka Ransom.;Laura Coates.;Sarah T Brown.
来源: Rheumatology (Oxford). 2025年64卷4期1750-1759页
Our objective was to determine whether early detection of undiagnosed PsA in a primary care psoriasis population improves outcome in physical function at 24 months post-registration.
756. Preventive effects of early immunosuppressive treatment on the development of interstitial lung disease in systemic sclerosis.
作者: Arthiha Velauthapillai.;M F R Bootsma.;Cosimo Bruni.;Christina Bergmann.;Marco Matucci-Cerinic.;David Launay.;Gabriela Riemekasten.;L Garzanova.;Paolo Airò.;Elena Rezus.;Jose A P da Silva.;Francesco Del Galdo.;Nicolas Hunzelmann.;Lorinda S Chung.;Dorota Krasowska.;Oliver Distler.;Cornelia H M van den Ende.;Madelon C Vonk.; .
来源: Rheumatology (Oxford). 2025年64卷SI期SI122-SI130页
Hypothesizing that early treatment yields improved prognosis, we aimed to investigate how the timing of immunosuppressive treatment relates to interstitial lung disease (ILD) development and the course of pulmonary function in systemic sclerosis (SSc).
757. Immunosuppressives discontinuation after renal response in lupus nephritis: predictors of flares, time to withdrawal and long-term outcomes.
作者: Alexandros Panagiotopoulos.;Eleni Kapsia.;Ioannis El Michelakis.;John Boletis.;Smaragdi Marinaki.;Petros P Sfikakis.;Maria G Tektonidou.
来源: Rheumatology (Oxford). 2025年64卷4期1894-1903页
The optimal duration of immunosuppressive (IS) treatment for lupus nephritis (LN) remains uncertain. We assessed the prevalence and predictors of IS tapering and discontinuation (D/C) in LN patients.
758. Development of a measuring app for systemic sclerosis-related digital ulceration (SALVE: Scleroderma App for Lesion VErification).
作者: Adrian K Davison.;Ashma Krishan.;Robert P New.;Andrea Murray.;Graham Dinsdale.;Joanne Manning.;Frances Hall.;John D Pauling.;Andy Vail.;Kathryn Kearney.;Helen Patrick.;Michael Hughes.;William Dixon.;Mark Dickinson.;Chris Taylor.;Ariane L Herrick.
来源: Rheumatology (Oxford). 2024年63卷12期3297-3305页
To test the hypothesis that photographs (in addition to self-reported data) can be collected daily by patients with SSc using a smartphone app designed specifically for digital lesions, and could provide an objective outcome measure for use in clinical trials.
759. Assessing the impact of health-care access on the severity of low back pain by country: a case study within the GBD framework.
作者: YiFan Wu.;Sarah Wulf Hanson.;Garland Culbreth.;Caroline Purcell.;Peter Brooks.;Jacek Kopec.;Lyn March.;Anthony D Woolf.;Maja Pasovic.;Erin Hamilton.;Damian Santomauro.;Theo Vos.
来源: Lancet Rheumatol. 2024年6卷9期e598-e606页
The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) is key for policy making. Low back pain is the leading cause of disability in terms of years lived with disability (YLDs). Due to sparse data, a current limitation of GDB is that a uniform severity distribution is presumed based on 12-Item Short Form Health Survey scores derived from US Medical Expenditure Panel Surveys (MEPS). We present a novel approach to estimate the effect of exposure to health interventions on the severity of low back pain by country and over time.
760. Trimethoprim sulfamethoxazole prophylaxis and serious infections in granulomatosis with polyangiitis treated with rituximab.
作者: Arielle Mendel.;Hassan Behlouli.;Évelyne Vinet.;Jeffrey R Curtis.;Sasha Bernatsky.
来源: Rheumatology (Oxford). 2025年64卷4期2041-2049页
To assess the association of trimethoprim sulfamethoxazole (TMP-SMX) prophylaxis with serious infections in rituximab-treated patients with granulomatosis with polyangiitis (GPA).
|